EMA Withdrawn: Starlix (nateglinide) — Novartis Europharm Limited

View source ↗

Summary

EMA withdrew Starlix (nateglinide) from the market for Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Starlix (nateglinide)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 08/11/2021